Olga Osipova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Olga Osipova has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Ana Maria Garcia Vicente
Nuclear Medicine Department, University Hospital of Toledo, 45007 Toledo, Spain
1 shared publication - Begoña Manzarbeitia-Arroba
Nuclear Medicine Department, University Hospital of Toledo, 45007 Toledo, Spain
1 shared publication - Marina Hodolic
Nuclear Medicine Research Department, Iason, Graz, Austria
1 shared publication - Robert Pichler
Institute of Nuclear Medicine Kepler University Hospital—Neuromed Campus, 4020 Linz, Austria
1 shared publication - Ángel Maria Soriano-Castrejón
Nuclear Medicine Department, University Hospital of Toledo, 45007 Toledo, Spain
1 shared publication
Latest Publications
- Open Access
18F-Fluoroethyl-L Tyrosine Positron Emission Tomography Radiomics in the Differentiation of Treatment-Related Changes from Disease Progression in Patients with Glioblastoma
The follow-up of glioma patients after therapeutic intervention remains a challenging topic, as therapy-related changes can emulate true progression in contrast-enhanced magnetic resonance imaging. 18F-fluoroethyl-tyrosine (18F-FET) is a radiopharmaceutical that accumulates in glioma cells due to an increased expression of L-amino acid transporters and, contrary to gadolinium, does not depend on blood–brain barrier disruption to reach tumoral cells. It has demonstrated a high diagnostic value in the differentiation of tumoral viability and pseudoprogression or any other therapy-related changes, especially when combining traditional visual analysis with modern radiomics. In this review, we aim to cover the potential role of 18F-FET positron emission tomography in everyday clinical practice when applied to the follow-up of patients after the first therapeutical intervention, early response evaluation, and the differential diagnosis between therapy-related changes and progression.
Open Access18F-Fluoroethyl-L Tyrosine Positron Emission Tomography Radiomics in the Differentiation of Treatment-Related Changes from Disease Progression in Patients with Glioblastoma
The follow-up of glioma patients after therapeutic intervention remains a challenging topic, as therapy-related changes can emulate true progression in contrast-enhanced magnetic resonance imaging. 18F-fluoroethyl-tyrosine (18F-FET) is a radiopharmaceutical that accumulates in glioma cells due to an increased expression of L-amino acid transporters and, contrary to gadolinium, does not depend on blood–brain barrier disruption to reach tumoral cells. It has demonstrated a high diagnostic value in the differentiation of tumoral viability and pseudoprogression or any other therapy-related changes, especially when combining traditional visual analysis with modern radiomics. In this review, we aim to cover the potential role of 18F-FET positron emission tomography in everyday clinical practice when applied to the follow-up of patients after the first therapeutical intervention, early response evaluation, and the differential diagnosis between therapy-related changes and progression.